ImmuPharma Chairman explains why the Avion deal is so significant – Nov 2019

ImmuPharma plc (LON: IMM) Non-Executive Chairman Tim McCarthy joins DirectorsTalk to discuss a licencing and development agreement with US speciality pharmaceutical company Avion. Tim talks us through the key highlights of the deal, provides background on Avion, the importance of this validation from an industry player, partners for other territories, the next key milestones, the Lanstead Agreement and why ImmuPharma is now a stock potential investors should be considering.